International Institute of Cancer Immunology, Inc.

Sumitomo Pharmaceuticals Company Limited

Sumitomo Dainippon Pharma Co., Ltd.

Chugai Seiyaku Kabushiki Kaisha

Dainippon Sumitomo Pharma Co., Ltd.

Other

Sumitomo Pharma Co., Ltd.

Sumitomo Manufacturing Company Limited

Masahiko Yamamoto

Toshio Nishihara

Masashi Gotoh

Yasuyuki Ueki

Chiang Jia Li

Hitoshi Ban

Masashi Goto

Yosuke Takanashi

Yukihiro Nishio

Yumiko Kamikawa

Ryu Nagata

Hisakazu Kishimoto

Kazuhito Ikeda

Tohru Tatsuno

Hiroki Ogo

Tatsuya Fujibayashi

Yoshiharu Ikeda

Keiichi Ono

Naoki Tohdoh

Hideo Agui

Tsunemasa Irie

Shin-ichi Kojima

Kosei Ojika

Nobuyuki Fukushima

Shin-ichiro Tojo

Yoshihara Ikeda

A compound represented by the formula (1): wherein Xand Yare each a single bond and the like, cancer antigen peptide A is an MHC class I-restricted WT1 peptide consisting of 7-30 amino acid residues, Ris a hydrogen atom, a group represented by the formula (2): wherein Xand Yare each a single bond and the like, cancer antigen peptide B has a sequence different from that of the cancer antigen peptide A, and is an MHC class I-restricted WT1 peptide consisting of 7-30 amino acid residues, or cancer antigen peptide C, and cancer antigen peptide C has a sequence different from that of the cancer antigen peptide A, and is an MHC class I-restricted WT1 peptide or an MHC class II-restricted WT1 peptide, consisting of 7-30 amino acid residues containing one cysteine residue, or a salt thereof, and the like.

WT1 antigen peptide conjugate vaccine

Method for cancer immunotherapy

A novel compound of the formula (1): wherein X is a tyrosine residue or a methionine residue; Y and Z each are a single bond or the like; Ris a hydrogen atom or the like; Ris a hydroxy group or the like; Ris a hydrogen atom, alkyl group, amino group or the like; Ris a hydrogen atom, alkyl group, carboxy group or the like; m is 1 or 2; and n is an integer of 0 to 2, with the proviso that when n is 0, Ris a hydrogen atom or an alkyl group, or a pharmaceutically acceptable salt thereof, and its use in cancer immunotherapy.

A compound of formula (1):  wherein X is a tyrosine residue or a methionine residue; Y and Z each are a single bond; Ris a hydrogen atom; Ris a hydroxy group; Ris a hydrogen atom, alkyl group, amino group substituted alkylcarbonylamino; Ris a hydrogen atom, alkyl group, carboxy group a group of formula (2): 

Peptides comprising an epitope of the wilms tumor gene product

A compound of the formula:wherein Ar is optionally substituted phenyl, etc.; n is 0, 1 or 2;

Amide derivative

The present invention relates to a 2,3-diaminopropionic acid derivative of the formula (1): ##STR1## or a pharmaceutically acceptable salt thereof. The compounds of the present invention are useful as a platelet aggregation inhibitor, a cancer metastasis inhibitor, a wound healing agent or a bone resorption inhibitor.

2,3-diaminopropionic acid derivative

The invention provides human- or rat-derived neurotrophic peptides and derivatives thereof, precursor peptides thereof, genes encoding the same, transformants containing recombinant expression vectors bearing the genes, and compositions comprising as an effective ingredient these neurotrophic peptides or derivatives thereof. The neurotrophic peptide or its derivatives of the present invention have a neurotrophic activity and are useful for the treatment of neuro-degenerative disorders and dementia.

Neurotrophic peptide derivatives

Dipiperidine derivatives

Growing community of inventors

Osaka, Japan

Toshio Nishihara